Hongyun Biotech
RedCloud Bio is an innovative pharmaceutical company specializing in the research and development of precision therapeutics for patients with cancer and other serious diseases with high unmet needs. They leverage a proprietary small molecule drug discovery platform that integrates structural pharmacology with advanced computational techniques such as molecular dynamics simulation, computational chemistry, and artificial intelligence. This platform allows them to efficiently develop innovative drugs targeting novel or known drug-resistant targets. The company has a strong R&D team with nearly 20 years of experience in structure-based drug design and has accumulated extensive data and models in exploring target-compound interactions and resistance mechanisms. Their lead product candidate, H002, is a small molecule drug developed for EGFR-mutated non-small cell lung cancer, which has entered clinical trials and is positioned as a potentially groundbreaking treatment.
Hongyun Biotech
RedCloud Bio is an innovative pharmaceutical company specializing in the research and development of precision therapeutics for patients with cancer and other serious diseases with high unmet needs. They leverage a proprietary small molecule drug discovery platform that integrates structural pharmacology with advanced computational techniques such as molecular dynamics simulation, computational chemistry, and artificial intelligence. This platform allows them to efficiently develop innovative drugs targeting novel or known drug-resistant targets. The company has a strong R&D team with nearly 20 years of experience in structure-based drug design and has accumulated extensive data and models in exploring target-compound interactions and resistance mechanisms. Their lead product candidate, H002, is a small molecule drug developed for EGFR-mutated non-small cell lung cancer, which has entered clinical trials and is positioned as a potentially groundbreaking treatment.